AbbVie’s Skyrizi shows promise as personalised treatment for psoriasis
The immunosuppressant reduced inflammation in patients with the skin condition after three days
Read More
Tag: risankizumab
Skyrizi bags NICE fast-track
Eligible patients in England and Wales will have access to the drug almost two months earlier.
Read More
NICE recommends Skyrizi, Forxiga
The recommendations are for the indication of plaque psoriasis and type I diabetes, respectively.
Read More
AbbVie files risankizumab in the US
AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.
Read More
AbbVie’s IL-23 blocker shows efficacy in psoriasis trial
An experimental therapy being developed by AbbVie for the treatment of patients with moderate to severe plaque psoriasis has hit key targets in a pivotal late-stage trial.
Read More
AbbVie’s risankizumab bags Orphan status for paediatric Crohn’s
An experimental therapy being developed by AbbVie for paediatric patients with Crohn’s disease has been awarded Orphan Drug status in the US.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
